Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
39.67
+0.47 (1.20%)
Nov 21, 2024, 12:19 PM EST - Market open

Company Description

Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.

It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.

The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.

Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte, Inc.
Veracyte logo
Country United States
Founded 2006
IPO Date Oct 30, 2013
Industry Diagnostics & Research
Sector Healthcare
Employees 815
CEO Marc Stapley

Contact Details

Address:
6000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States
Phone 650 243 6300
Website veracyte.com

Stock Details

Ticker Symbol VCYT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001384101
CUSIP Number 92337F107
ISIN Number US92337F1075
Employer ID 20-5455398
SIC Code 8071

Key Executives

Name Position
Marc A. Stapley Chief Executive Officer and Director
Rebecca Chambers Executive Vice President and Chief Financial Officer
Dr. Phillip G. Febbo M.D. Chief Scientific and Medical Officer
Annie McGuire Executive Vice President, General Counsel and Chief People Officer
Dr. John Leite Ph.D. Chief Commercial Officer for CLIA Business
Jonathan Wygant Vice President and Chief Accounting Officer
Steven French Senior Vice President and Chief Information Officer
Karen Possemato Senior Vice President of Corporate Marketing, Communications and Commercial Operations
Robert Brainin Executive Vice President and Chief Business Officer
Corinne Danan Senior Vice President

Latest SEC Filings

Date Type Title
Nov 19, 2024 144 Filing
Nov 12, 2024 144 Filing
Nov 12, 2024 144 Filing
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Oct 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 4, 2024 144 Filing
Sep 4, 2024 8-K Current Report